Delcath Fulfills Nasdaq Independent Director and Audit Committee Requirements With Addition of Two New Directors

STAMFORD, Conn.--June 13, 2007--Delcath Systems, Inc. (Nasdaq:DCTH) has received notice from the Nasdaq Stock Market ("Nasdaq") that following the recent addition of Laura A. Philips, Ph.D., MBA and Jonathan J. Lewis M.D., Ph.D., to the Company's Board of Directors, Delcath is now in compliance with Nasdaq's Marketplace Rule 4350, which requires its Board to have a majority of independent directors and requires its audit committee to have three members. Delcath also received a letter from the Boston Stock Exchange ("BSE") informing the company that it is now in compliance with the BSE requirements concerning independent directors.

Dr. Philips, the Chair of the Board of Directors of Planned Parenthood of New York City and a director of Boyce Thompson Institute, is the former Chief Operating Officer and Acting Chief Financial Officer of NexGenix Pharmaceuticals. Dr. Lewis, a surgical oncologist, is Chief Executive Officer of ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP).

About Delcath Systems, Inc.
Delcath Systems is a developer of percutaneous perfusion technology for organ or region-specific delivery of therapeutic and chemotherapeutic agents. The Delcath system is currently being tested with the drug Melphalan in a Phase III trial of patients with metastatic ocular and cutaneous melanoma in the liver and a Phase II trial of patients with primary liver cancers and metastatic tumors in the liver from neuroendocrine cancers and adenocarcinomas. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis including the US, Europe, Asia and Canada. For more information, please visit the Company's website www.delcath.com.

This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.